Study of REGN3500 and Dupilumab in Patients With Asthma
Completed · Phase 1 · Has a placebo group
Conditions studied: Asthma, Allergic
In brief
To assess the effects of REGN3500, dupilumab, and REGN3500 plus dupilumab, compared with placebo, on changes in inflammatory gene expression signatures in sputum induced after a bronchial allergen challenge (BAC) in adults with mild allergic asthma, at week 4 after treatment initiation compared with those at screening.
Key facts
- Study ID
- NCT03112577
- Run by
- Regeneron Pharmaceuticals
- People needed
- 32
- Starts
- 2017-06-15
- Expected to finish
- 2019-12-09
- Last updated by the study team
- 2020-01-18
Who can join
Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.
Where it is running
- WCCT Global — Cypress, California, United States
- Celerion — Belfast, United Kingdom
- Hammersmith Medicine Research — London, United Kingdom
- Respiratory Clinical Trials Ltd — London, United Kingdom
- The Medicines Evaluation Unit — Manchester, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.